For the year ending 2025-12-31, NVAX made $1,123,479K in revenue. $440,302K in net income. Net profit margin of 39.19%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Revenues | 1,123,479 | 682,162 | ||
| Cost of sales | 73,040 | 202,739 | ||
| Research and development | 342,320 | 391,169 | ||
| Selling, general, and administrative | 157,479 | 337,185 | ||
| Impairment of assets held for sale | 97,845 | - | ||
| Total expenses | 670,684 | 931,093 | ||
| Income (loss) from operations | 452,795 | -248,931 | ||
| Interest expense | 22,547 | 20,075 | ||
| Loss on debt extinguishment | -28,714 | - | ||
| Gain on disposition of novavax cz assets | 0 | 51,949 | ||
| Other income, net | 40,633 | 40,442 | ||
| Income (loss) before income tax expense | 442,167 | -176,615 | ||
| Income tax expense | 1,865 | 10,884 | ||
| Net income (loss) | 440,302 | -187,499 | ||
| Basic EPS | 2.72 | -1.23 | ||
| Diluted EPS | 2.58 | -1.23 | ||
| Basic Average Shares | 161,991,000 | 152,190,000 | ||
| Diluted Average Shares | 173,103,000 | 152,190,000 | ||
NOVAVAX INC (NVAX)
NOVAVAX INC (NVAX)